RNS Number : 8794N
Pharma C Investments PLC
27 September 2023

27 September 2023

Result of General Meeting

Pharma C Investments Plc ("**Pharma C**" or the "**Company**") announces that, further to the announcement of 22 September 2023, at the general meeting ("GM") held today at the offices of Hill Dickinson LLP, the resolutions were withdrawn and not put to members as the requisition convening the GM was withdrawn.

Prior to the requisition being withdrawn, the Company had received the following proxy appointments:

	Chairman of the meeting FOR		Chairman of the meeting AGAINST		Chairman of the meeting DISCRETION		ABSTAIN	
	Cards	Votes	Cards	Votes	Cards	Votes	Cards	Votes
Ordinary Resolution 1	0	0	3	52,637,360	1	1,428,571	0	0
Ordinary Resolution 2	0	0	4	54,065,931	0	0	0	0
Ordinary Resolution 3	0	0	4	54,065,931	0	0	0	0

Further to the announcement made on 30 June 2023, the Company announces that it continues to work with its auditors to publish its audited financial statements for the year ended 31 December 2022 and will provide updates in due course.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

The Directors of Pharma C accept responsibility for this announcement.

END

For additional information please contact:

Pharma C Investments

Gavin Sathianathan, Investment Strategy Director

gavin@pharmacinvestments.com

Novum Securities (AQSE Corporate Adviser)

Tel: +44 207 399 9400

David Coffman

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXSEDFLWEDSESU